Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Investing.com -- Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong ...

Investing.com - Berenberg ha rebajado su calificación de GSK plc (LON: GSK) a "Hold" desde "Buy", una decisión impulsada por el sólido rendimiento de la acción en lo que va del año y una esperada ...

Recent developments include a broader-than-expected approval for Nucala in COPD and a positive CHMP opinion for Blenrep, alongside a new acquisition of the Phase 3-ready efimosfermin for liver disease ...

MAX BARNHART GSK buys liver drug for $1.2 billion GSK is spending $1.2 billion up front and promising up to $800 million more for the rights to a liver disease drug candidate called efimosfermin alfa.

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals' lead pipeline candidate, efimosfermin alfa ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 ...